0001589150 false 09/30 2022 Q2 0001589150 2021-10-01 2022-03-31 0001589150 2022-04-07 0001589150 2022-03-31 0001589150 2021-09-30 0001589150 us-gaap:SeriesAPreferredStockMember 2022-03-31 0001589150 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2022-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesMMember 2022-03-31 0001589150 RGBP:SeriesMMember 2021-09-30 0001589150 RGBP:SeriesNCMember 2022-03-31 0001589150 RGBP:SeriesNCMember 2021-09-30 0001589150 2022-01-01 2022-03-31 0001589150 2021-01-01 2021-03-31 0001589150 2020-10-01 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2020-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2020-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2020-09-30 0001589150 us-gaap:CommonStockMember 2020-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2020-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001589150 us-gaap:RetainedEarningsMember 2020-09-30 0001589150 RGBP:ContributedCapitalMember 2020-09-30 0001589150 2020-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2020-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2020-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2020-12-31 0001589150 us-gaap:CommonStockMember 2020-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2020-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-12-31 0001589150 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-09-30 0001589150 RGBP:SeriesAAPreferredStockMember 2021-09-30 0001589150 RGBP:SeriesNCPreferredStockMember 2021-09-30 0001589150 us-gaap:CommonStockMember 2021-09-30 0001589150 RGBP:SeriesMPreferredStockMember 2021-09-30 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001589150 us-gaap:RetainedEarningsMember 2021-09-30 0001589150 RGBP:ContributedCapitalMember 2021-09-30 0001589150 RGBP:PreferredStockSeriesAMember 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-12-31 0001589150 us-gaap:CommonStockMember 2021-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001589150 us-gaap:RetainedEarningsMember 2021-12-31 0001589150 RGBP:ContributedCapitalMember 2021-12-31 0001589150 2021-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2020-10-01 2020-12-31 0001589150 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2020-10-01 2020-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001589150 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001589150 RGBP:ContributedCapitalMember 2020-10-01 2020-12-31 0001589150 2020-10-01 2020-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-01-01 2021-03-31 0001589150 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-01-01 2021-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001589150 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001589150 RGBP:ContributedCapitalMember 2021-01-01 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-10-01 2021-12-31 0001589150 us-gaap:CommonStockMember 2021-10-01 2021-12-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-10-01 2021-12-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-10-01 2021-12-31 0001589150 us-gaap:RetainedEarningsMember 2021-10-01 2021-12-31 0001589150 RGBP:ContributedCapitalMember 2021-10-01 2021-12-31 0001589150 2021-10-01 2021-12-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-01-01 2022-03-31 0001589150 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-01-01 2022-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001589150 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001589150 RGBP:ContributedCapitalMember 2022-01-01 2022-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2021-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2021-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2021-03-31 0001589150 us-gaap:CommonStockMember 2021-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2021-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001589150 us-gaap:RetainedEarningsMember 2021-03-31 0001589150 RGBP:ContributedCapitalMember 2021-03-31 0001589150 2021-03-31 0001589150 RGBP:PreferredStockSeriesAMember 2022-03-31 0001589150 RGBP:SeriesAAPreferredStockMember 2022-03-31 0001589150 RGBP:SeriesNCPreferredStockMember 2022-03-31 0001589150 us-gaap:CommonStockMember 2022-03-31 0001589150 RGBP:SeriesMPreferredStockMember 2022-03-31 0001589150 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001589150 us-gaap:RetainedEarningsMember 2022-03-31 0001589150 RGBP:ContributedCapitalMember 2022-03-31 0001589150 srt:MinimumMember 2021-10-01 2022-03-31 0001589150 srt:MaximumMember 2021-10-01 2022-03-31 0001589150 RGBP:ZanderTherapeuticsMember 2022-03-31 0001589150 2012-04-24 2022-03-31 0001589150 RGBP:DavidKoosMember 2022-03-31 0001589150 RGBP:DavidKoosMember 2022-03-31 0001589150 RGBP:DavidKoosMember 2021-10-01 2022-03-31 0001589150 RGBP:March82016Member 2022-03-31 0001589150 RGBP:April62016Member 2022-03-31 0001589150 RGBP:October312016Member 2022-03-31 0001589150 RGBP:October3120161Member 2022-03-31 0001589150 RGBP:October3120162Member 2022-03-31 0001589150 RGBP:March132017Member 2022-03-31 0001589150 RGBP:March132017Member 2021-10-01 2022-03-31 0001589150 RGBP:March312017Member 2022-03-31 0001589150 RGBP:March3120171Member 2022-03-31 0001589150 RGBP:March3120171Member 2021-10-01 2022-03-31 0001589150 RGBP:April192017Member 2022-03-31 0001589150 RGBP:May52017Member 2022-03-31 0001589150 RGBP:May52017Member 2021-10-01 2022-03-31 0001589150 RGBP:June262017Member 2022-03-31 0001589150 RGBP:June262017Member 2021-10-01 2022-03-31 0001589150 RGBP:Sept252017Member 2022-03-31 0001589150 RGBP:Sept252017Member 2021-10-01 2022-03-31 0001589150 RGBP:Oct0317Member 2022-03-31 0001589150 RGBP:Oct0317Member 2021-10-01 2022-03-31 0001589150 RGBP:Oct1617Member 2022-03-31 0001589150 RGBP:Oct1617Member 2021-10-01 2022-03-31 0001589150 RGBP:Nov0117Member 2022-03-31 0001589150 RGBP:Nov0117Member 2021-10-01 2022-03-31 0001589150 RGBP:Nov0120172Member 2022-03-31 0001589150 RGBP:Nov0120172Member 2021-10-01 2022-03-31 0001589150 RGBP:Dec2017Member 2022-03-31 0001589150 RGBP:Dec2017Member 2021-10-01 2022-03-31 0001589150 RGBP:Feb2818Member 2022-03-31 0001589150 RGBP:Feb2818Member 2021-10-01 2022-03-31 0001589150 RGBP:July112018Member 2022-03-31 0001589150 RGBP:July112018Member 2021-10-01 2022-03-31 0001589150 RGBP:September302018Member 2022-03-31 0001589150 RGBP:September302018Member 2021-10-01 2022-03-31 0001589150 RGBP:July192019Member 2022-03-31 0001589150 RGBP:September172021Member 2022-03-31 0001589150 RGBP:September172021Member 2021-10-01 2022-03-31 0001589150 RGBP:March172022Member 2022-03-31 0001589150 RGBP:ZanderTherapeuticsMember 2019-05-30 2019-06-11 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2019-11-01 2019-11-29 0001589150 RGBP:ZanderTherapeuticsMember 2021-10-01 2022-03-31 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2021-10-01 2022-03-31 0001589150 RGBP:SeriesMMember RGBP:ZanderTherapeuticsMember 2022-03-31 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2022-03-31 0001589150 us-gaap:CommonStockMember RGBP:ZanderTherapeuticsMember 2021-10-01 2022-03-31 0001589150 RGBP:UnrelatedPartyMember 2021-04-01 2021-06-30 0001589150 RGBP:UnrelatedPartyMember 2021-07-01 2021-09-30 0001589150 us-gaap:CommonStockMember 2022-03-31 0001589150 us-gaap:CommonStockMember RGBP:OncologyPharmaMember 2022-03-31 0001589150 us-gaap:CommonStockMember RGBP:OncologyPharmaMember 2021-10-01 2022-03-31 0001589150 us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-03-01 2022-03-28 0001589150 us-gaap:SubsequentEventMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-04-01 2022-04-04 0001589150 us-gaap:SubsequentEventMember us-gaap:ConvertibleDebtMember us-gaap:CommonStockMember 2022-04-01 2022-04-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the quarterly period ended March 31, 2022

 

 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 For the transition period from

 

 Commission File No. 333-191725

 

 REGEN BIOPHARMA, INC.

(Exact name of small business issuer as specified in its charter)

 

Nevada 45-5192997
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

 

4700 Spring Street, St 304, La Mesa, California 91942

(Address of Principal Executive Offices)

 

619 722-5505

(Issuer’s telephone number)

 

None

(Former name, address and fiscal year, if changed since last report)

 

Check whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒   No  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐  No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer,” “non-accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

☐  Large accelerated filer ☐  Accelerated filer
☐  Non-accelerated filer ☒  Smaller reporting company
  ☐ Emerging Growth Company 

APPLICABLE ONLY TO CORPORATE ISSUERS:

As of April 7, 2022 Regen Biopharma, Inc. had 4,736,002,832  common shares outstanding.

As of April 7,2022 Regen Biopharma, Inc. had 439,293,406 shares of Series A Preferred Stock outstanding.

As of April 7, 2022 Regen Biopharma, Inc. had 50,000 shares of Series AA Preferred Stock outstanding.

As of April 7, 2022 Regen Biopharma, Inc. had 44,000,000 shares of Series M Preferred Stock outstanding.

As of April 7, 2022 Regen Biopharma, Inc. had 10,000 shares of Series NC Preferred Stock outstanding

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):

Yes ☐ No ☒

  1  

 

 

PART I - FINANCIAL INFORMATION

Item 1. - Financial Statements

                 
REGEN BIOPHARMA , INC.        
CONDENSED CONSOLIDATED BALANCE SHEETS        
         
         
    As of March 31, 2022   As of September 30, 2021
    (Unaudited)    
ASSETS        
CURRENT ASSETS                
Cash   $ 234,674     $ 727,162  
Accounts Receivable, Related Party     268,042       213,192  
Note Receivable, Related Party     5,396       5,396  
Accrued Interest Receivable     496       230  
Prepaid Expenses     34,582       48,144  
     Total Current Assets     543,190       994,124  
OTHER ASSETS                
Investment Securities     67,710       198,006  
Investment Securities, Related Party     19,969       19,969  
Total Other Assets     87,679       217,975  
TOTAL ASSETS   $ 630,869     $ 1,212,099  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY                
Current Liabilities:                
Accounts payable     41,629       91,498  
Notes Payable     227       1,429,179  
Accrued payroll taxes     4,241       4,241  
Accrued Interest     664,787       954,861  
Accrued Rent     —        0  
Accrued Payroll     1,266,679       1,266,679  
Other Accrued Expenses     41,423       41,423  
Bank Overdraft     1,000       1,000  
Due to Investor     20,000       20,000  
Unearned Income     1,781,222       1,843,806  
Derivative Liability     70,561,820       6,892,477  
Convertible Notes Payable Less  unamortized discount     2,987,270       2,131,311  
Convertible Notes Payable, Related Parties Less  unamortized discount     10,000       21,500  
Total Current Liabilities     77,380,299       14,697,976  
Long Term Liabilities:                
Convertible Notes Payable, Related Parties Less  unamortized discount     —        0  
Total Long Term Liabilities                
Total Liabilities     77,380,299       14,697,976  
                 
STOCKHOLDERS' EQUITY (DEFICIT)                
Common Stock ($.0001 par value) 500,000,000 shares authorized; 5,800,000,000 authorized and 4,580,002,832 issued and outstanding as of March 31,2022 and 4,800,000,000 authorized and 4,350,554,514 shares issued and outstanding as of September 30 ,2021.     457,999       435,054  
Preferred Stock, 0.0001 par value, 800,000,000 authorized as of     —        —   
March  31,2022  and September 30,2021 respectively     —        —   
Series A Preferred 300,000,000 authorized as of September 30,2021 and 540,000,000 authorized as of March 31, 2022; 439,293,406 and 431,998,817 outstanding as of  March 31,2022 and September 30, 2021 respectively     43,929       43,200  
Series AA Preferred $0.0001 par value 600,000 authorized and 50,000 and 50,000   outstanding as of March 31, 2022 and September 30,2021 respectively     5       5  
Series M Preferred $0.0001 par value 300,000,000 authorized and  44,000,000 outstanding as of September 30,2021 and 60,000,000 authorized and 44,000,000 outstanding as of March 31, 2022     4,400       4,400  
Series NC Preferred $0.0001 par value 20,000  authorized and 10,000  outstanding as of September 30, 2021 and March 31,2022 respectively     1       1  
Additional Paid in capital     9,793,419       8,644,037  
Contributed Capital     736,326       736,326  
Retained Earnings (Deficit)     (87,785,509 )     (23,348,900 )
Total Stockholders' Equity (Deficit)     (76,749,430 )     (13,485,877 )
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)   $ 630,869     $ 1,212,099  
                 
The Accompanying Notes are an Integral Part of These Financial Statements

  2  

 

                                 
REGEN BIOPHARMA , INC.                
CONDENSED CONSOLIDATED  STATEMENTS OF OPERATIONS        
( Unaudited)                
                 
      Quarter Ended March 31, 2022       Quarter Ended March 31, 2021       Six Months Ended March 31, 2022       Six Months Ended March 31, 2021  
REVENUES                                
Revenues   $ 30,945     $ —       $ 62,584     $ —    
Revenues, Related Party     27,425       27,425       54,849       54,849  
TOTAL REVENUES     58,369       27,425       117,434       54,849  
COST AND EXPENSES                                
Research and Development     27,390       512       62,809       1,639  
Research and Development, Related Party     36,975       0       117,250       0  
General and Administrative     5,355       39,886       12,013       84,664  
Consulting and Professional Fees     50,143       0       88,279       0  
Rent     15,000       0       20,000       0  
Total Costs and Expenses     134,863       40,398       300,351       86,303  
OPERATING INCOME (LOSS)   $ (76,494 )   $ (12,973 )   $ (182,917 )   $ (31,453 )
                                 
OTHER INCOME & (EXPENSES)                                
Interest Income     131       0       266       0  
Interest Expense     (42,561 )     (65,247 )     (77,571 )     (138,459 )
Interest Expense attributable to Amortization of Discount     (21,977 )     (9,932 )     (44,428 )     (46,649 )
Penalties     (300,000 )     0       (300,000 )     0  
Unrealized Gain ( Loss) on sale of Investment Securities     (6,405 )     0       (130,296 )     0  
Gain (Loss) on derecognition of Accounts Payable     0       0       62,700       0  
Derivative Income (Expense)     (66,634,282 )     530,335       (63,669,343 )     2,325,111  
Gain (Loss) on  Extinguishment Convertible Debt     0       —        (95,019 )     0  
TOTAL OTHER INCOME (EXPENSE)     (67,005,095 )     455,156       (64,253,692 )     2,140,002  
                                 
NET INCOME (LOSS)   $ (67,081,589 )   $ 442,183     $ (64,436,609 )   $ 2,108,549  
NET INCOME (LOSS) attributable to common shareholders   $ (67,081,589 )   $ 382,046     $ (64,436,609 )   $ 1,821,787  
                                 
BASIC AND FULLY DILUTED EARNINGS (LOSS) PER SHARE   $ (0.015 )   $ 0.0002     $ (0.014 )   $ 0.00086  
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING     4,564,542,158       2,457,641,499       4,535,585,981       2,125,778,002  
                                 
The Accompanying Notes are an Integral Part of These Financial Statements

  3  

 

 

                                                                                                                         
REGEN BIOPHARMA , INC.
Condensed Consolidated Statement of Shareholder's Deficit
(Unaudited)
                                                             
                                                             
    Series A  Preferred   Series AA Preferred   Series NC Preferred   Common   Series M Peferred                    
    Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount   Additional Paid-in Capital   Retained Earnings   Contributed Capital   Total    
Balance September 30, 2020     381,768,689     $ 38,177       50,000       5       —                1,605,000,246     $ 160,498       44,000,000     $ 4,400     $ 8,313,876     $ (16,583,666 )   $ 731,711     $ (7,334,998 )        
Shares issued for Debt                                                     57,726,183       5,773                       (2,021 )                     3,752          
Shares Issued For Interest                                                     22,339,663       2,234                       (782 )                     1,452          
Shares issued for Debt                                                     60,007,919       6,001                       (2,101 )                     3,900          
Shares Issued For Interest                                                     23,926,234       2,393                       (838 )                     1,555          
Shares issued for Debt                                                     60,834,498       6,083                       1,217                       7,300          
Shares Issued For Interest                                                     26,185,501       2,619                       523                       3,142          
Shares issued for Debt                                                     3,300,000       330                       99                       429          
Shares Issued For Interest                                                     1,819,077       182                       54                       236          
Shares issued for Fees                                                     1,228,077       123                       36                       159          
Shares issued for Debt                                                     62,003,571       6,200                       (2,170 )                     4,030          
Shares Issued For Interest                                                     26,155,352       2,616                       (916 )                     1,700          
Shares issued for Debt                                                     68,333,539       6,833                       1,367                       8,200          
Shares Issued For Interest                                                     14,883,378       1,488                       212                       1,700          
Shares issued for Debt     20,000,437       2,000                                                                       11,000                       13,000          
Shares Issued For Interest     12,378,732       1,238                                                                       6,808                       8,046          
Shares Issued for Debt                                                     88,888,889       8,889                       7,111                       16,000          
Shares Issued For Interest                                                     19,555,555       1,956                       1,294                       3,250          
Shares issued for Debt                                                     82,004,603       8,200                       (2,870 )                     5,330          
Shares Issued For Interest                                                     35,832,781       3,583                       (1,254 )                     2,329          
Additions to Contributed Capital                                     —        —                                                        1,865       1,865          
Net Loss     —        —       —        —                        —        —        —        —        —        1,666,367       —        1,666,367          
Balance December 31, 2020     414,147,858     $ 41,415       50,000       5       —                2,260,025,066     $ 226,001       44,000,000     $ 4,400     $ 8,330,646     $ (14,917,299 )   $ 733,576     $ (5,581,256 )        
shares issued for debt                                                     85,900,000       8,590                       (3,436 )                     5,154          
shares issued for interest                                                     88,000,000       8,800                       (4,400 )                     4,400          
shares issued for debt                                                     71,430,421       7,143                       22,857                       30,000          
shares issued for interest                                                     11,328,865       1,133                       3,625                       4,758          
shares issued for debt                                                     80,928,505       8,093                       (2,833 )                     5,260          
shares issued for interest                                                     38,341,033       3,834                       (1,342 )                     2,492          
shares issued for debt                                                     67,175,355       6,718                       (3,361 )                     3,357          
shares issued for interest                                                     8,824,645       882                       (441 )                     441          
shares issued for debt                                                     16,666,667       1,667                       (667 )                     1,000          
shares issued for interest                                                     95,833,333       9,583                       (3,833 )                     5,750          
shares issued for debt                                                     68,319,520       6,832                       (3,417 )                     3,415          
shares issued for interest                                                     1,680,480       168                       (84 )                     84          
shares issued for debt                                                     38,519,260       3,852                       (1,927 )                     1,925          
shares issued for interest                                                     1,480,740       148                       (74 )                     74          
Additions to Contributed Capital                                                                                                     250       250          
Net Income     —        —        —        —        —        —        —        —        —        —        —        442,183       —        4,421,825,363          
Balance March 31, 2021     414,147,858     $ 41,415       50,000       5       0       0       2,934,453,890     $ 293,444       44,000,000     $ 4,400     $ 8,331,313     $ (14,475,117 )   $ 733,826     $ (5,070,713 )        
Balance September 30, 2021     431,998,817     $ 43,200       50,000     $ 5       10,000     $ 1       4,350,554,514     $ 435,054       44,000,000     $ 4,400     $ 8,644,037     $ (23,348,900 )   $ 736,326     $ (13,485,877 )        
Shares issued for Debt                                                     10,000,000       1,000                       99,000                       100,000          
Shares issued for Interest                                                     2,666,200       267                       26,395                       26,662          
Shares issued for Debt                                                     10,000,000       1,000                       99,000                       100,000          
Shares issued for Interest                                                     3,883,700       388                       38,449                       38,837          
Shares issued for Debt                                                     6,022,971       602                       49,398                       50,000          
Shares issued for Interest                                                     2,361,366       236                       19,367                       19,603          
Shares issued for Debt                                                     15,503,953       1,550                       48,450                       50,000          
Shares issued for Interest                                                     5,759,719       576                       17,999                       18,575          
Shares issued for Interest                                                     23,255,888       2,326                       72,674                       75,000          
Shares issued for Debt                                                     9,945,768       995                       31,080                       32,075          
Shares issued for Interest                                                     7,751,973       775                       24,225                       25,000          
Shares issued for Interest                                                     3,211,178       321                       10,035                       10,356          
Shares issued for Debt                                                     1,000,016       100                       24,900                       25,000          
Shares issued for Interest                                                     355,326       36                       8,847                       8,883          
Shares issued for Debt     4,000,047       400                                                                       49,600                       50,000          
Shares issued for Interest     1,869,542       187                                                                       23,182                       23,369          
Shares issued for Debt                                                     10,256,427       1,026                       98,974                       100,000          
Shares issued for Interest                                                     4,082,878       408                       39,400                       39,808          
Shares issued for Debt                                                     8,421,053       842                       39,158                       40,000          
Shares issued for Interest                                                     2,987,789       299                       13,893                       14,192          
Shares issued for Debt                                                     6,250,082       625                       49,375                       50,000          
Shares issued for Interest                                                     2,376,531       238                       18,774                       19,012          
Shares issued for Debt                                                     72,476,800       7,248                       3,716                       10,964          
Shares issued for Debt                                                     1,000,014       100                       24,900                       25,000          
Shares issued for Interest                                                     461,086       46                       11,481                       11,527          
Shares issued for Debt                                                     2,400,000       240                       59,760                       60,000          
Shares issued for Interest                                                     1,017,600       102                       25,338                       25,440          
Shares issued for Debt     1,000,000       100                                                                       24,900                       25,000          
Shares issued for Interest     425,000       43                                                                       10,583               —        10,625          
Net Loss     —        —        —        —        —        —        —        —        —        —        —        2,644,980       —        2,644,980          
Balance December 31, 2021     439,293,406     $ 43,929       50,000     $ 5       10,000     $ 1